Literature DB >> 27647369

Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties.

Fen Jiang1, Hui-Jie Wang1, Qi-Chao Bao1, Lei Wang1, Yu-Hui Jin1, Qiong Zhang1, Di Jiang1, Qi-Dong You2, Xiao-Li Xu3.   

Abstract

Heat shock protein 90 (Hsp90) as a molecular target for oncology therapeutics has attracted much attention in the last decade. The Hsp90 multichaperone complex has important roles in the growth and/or survival of cancer cells. Cdc37, as a cochaperone, associates kinase clients to Hsp90 and promotes the development of malignant tumors. Disrupting the Hsp90-Cdc37 interaction provides an alternative strategy to inhibit the function of Hsp90 for cancer therapy. Celastrol, as a natural product, can disrupt the Hsp90-Cdc37 interaction and induce degradation of kinase clients. The study conducted here attempted to elucidate the structure-activity relationship of celastrol derivatives as Hsp90-Cdc37 disruptors and to improve the druglike properties. 23 celastrol derivatives were designed, synthesized, and the biological activities and physicochemical properties were determined. The derivative CEL20 showed improved Hsp90-Cdc37 disruption activity, anti-proliferative activities as well as druglike properties. Additionally, CEL20 induced clients degradation, cell cycle arrest and apoptosis in Panc-1 cells. This study can provide reference for the discovery of novel Hsp90-Cdc37 disruptors.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Celastrol; Druglike properties; HTRF; Hsp90–Cdc37 interaction; Structure–activity relationship

Mesh:

Substances:

Year:  2016        PMID: 27647369     DOI: 10.1016/j.bmc.2016.08.070

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  9 in total

1.  Hsp90 activator Aha1 drives production of pathological tau aggregates.

Authors:  Lindsey B Shelton; Jeremy D Baker; Dali Zheng; Leia E Sullivan; Parth K Solanki; Jack M Webster; Zheying Sun; Jonathan J Sabbagh; Bryce A Nordhues; John Koren; Suman Ghosh; Brian S J Blagg; Laura J Blair; Chad A Dickey
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-21       Impact factor: 11.205

2.  Native Endophytes of Tripterygium wilfordii-Mediated Biotransformation Reduces Toxicity of Celastrol.

Authors:  Ping-Yang Ma; Wei-Ling Geng; Hong-Yan Ji; Bang-Wen Yue; Cheng Liu; Sa Wang; Zhi-Bo Jiang; Jing Chen; Xiu-Li Wu
Journal:  Front Microbiol       Date:  2022-05-25       Impact factor: 6.064

Review 3.  A Mechanistic Overview of Triptolide and Celastrol, Natural Products from Tripterygium wilfordii Hook F.

Authors:  Shao-Ru Chen; Yan Dai; Jing Zhao; Ligen Lin; Yitao Wang; Ying Wang
Journal:  Front Pharmacol       Date:  2018-02-14       Impact factor: 5.810

4.  Synthesis and characterisation of celastrol derivatives as potential anticancer agents.

Authors:  Hong-Jian Zhang; Guo-Rui Zhang; Hu-Ri Piao; Zhe-Shan Quan
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

5.  Design, Synthesis and In Vitro Investigation of Novel Basic Celastrol Carboxamides as Bio-Inspired Leishmanicidal Agents Endowed with Inhibitory Activity against Leishmania Hsp90.

Authors:  Ivan Bassanini; Silvia Parapini; Erica E Ferrandi; Elena Gabriele; Nicoletta Basilico; Donatella Taramelli; Anna Sparatore
Journal:  Biomolecules       Date:  2021-01-05

Review 6.  Celastrol: A Review of Useful Strategies Overcoming its Limitation in Anticancer Application.

Authors:  Jinfeng Shi; Jiaxin Li; Ziyi Xu; Liang Chen; Ruifeng Luo; Chen Zhang; Fei Gao; Jinming Zhang; Chaomei Fu
Journal:  Front Pharmacol       Date:  2020-11-18       Impact factor: 5.810

Review 7.  Targeting Chaperone/Co-Chaperone Interactions with Small Molecules: A Novel Approach to Tackle Neurodegenerative Diseases.

Authors:  Lisha Wang; Liza Bergkvist; Rajnish Kumar; Bengt Winblad; Pavel F Pavlov
Journal:  Cells       Date:  2021-09-29       Impact factor: 6.600

8.  Synthesis and biological evaluation of celastrol derivatives as potent antitumor agents with STAT3 inhibition.

Authors:  Shaohua Xu; Ruolan Fan; Lu Wang; Weishen He; Haixia Ge; Hailan Chen; Wen Xu; Jian Zhang; Wei Xu; Yaqian Feng; Zhimin Fan
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

Review 9.  The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition.

Authors:  Michael A Serwetnyk; Brian S J Blagg
Journal:  Acta Pharm Sin B       Date:  2020-11-24       Impact factor: 11.413

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.